newsXIGDUO™ (dapagliflozin and metformin hydrochloride) approved in the European Union for type 2 diabetesAstraZeneca and Bristol-Myers Squibb announced that Xigduo™ has been granted…22 January 2014 | By AstraZenecaAstraZeneca and Bristol-Myers Squibb announced that Xigduo™ has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union...
newsU.S. FDA grants priority review for MetreleptinMetreleptin, an investigational agent for treatment of metabolic disorders associated…4 June 2013 | By Bristol-Myers Squibb CompanyMetreleptin, an investigational agent for treatment of metabolic disorders associated with rare forms of LD...